Nxera Pharma Co (4565.T) Osake Kurssi
Nxera Pharma Co Kurssi
Viimeisten 19 vuoden aikana Nxera Pharma Con liikevaihto kasvoi 21,4 % vuodessa ja ylsi 29,62 Mrd. JPY:een. Osakekohtainen tulos on laskenut 13,5 % vuodessa viimeisten 10 vuoden aikana. Nxera Pharma Con nettomarginaali −42,3 % on laskenut verrattuna 5,7 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 0,17 %. Nxera Pharma Con 12 kuukauden konsensustavoitehinta on 1 224,00 JPY, noin ali kurssia 14,3 %. 13 analyytikosta 11 suosittaa ostoa — kokonaiskonsensus on Osta.
Nxera Pharma Co osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Nxera Pharma Co liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Nxera Pharma Co -osakkeesta
The business model of Sosei Group Corp. focuses on discovering, developing, and commercializing innovative medicines. Sosei Group Corp. operates through two primary business segments: “Discovery and Early Development” and “Late-stage Development and Commercialization”. The company collaborates with global partners to research and create novel drugs and therapies addressing unmet medical needs in various therapeutic areas, including respiratory, neurology, and oncology. Sosei Group Corp. aims to leverage its proprietary technologies and expertise in drug discovery and development to deliver life-changing treatments to patients worldwide.
Sosei Group Corp is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Sosei Group Corp in the market include multinational pharmaceutical companies such as Roche Holding AG, Novartis AG, and Pfizer Inc. These companies are also engaged in the research, development, and commercialization of innovative drugs and therapies. However, Sosei Group Corp stands out in the market due to its unique focus on drug discovery and development, utilizing its proprietary platform technologies. As a global biopharmaceutical company, Sosei Group Corp strives to differentiate itself and expand its product portfolio in its pursuit of breakthrough treatments and therapies.
Sosei Group Corp. is a renowned pharmaceutical company with a rich history and profound background. Founded in 1990, Sosei Group Corp. is headquartered in Tokyo, Japan. The company focuses on discovering, developing, and commercializing innovative medicines for various therapeutic areas. Sosei Group Corp. has a strong track record of successfully bringing novel drugs to market, addressing significant medical needs worldwide. With a team of experienced researchers and development experts, the company emphasizes cutting-edge technologies and collaborations to drive its discoveries. Sosei Group Corp. is committed to improving patients' lives through its groundbreaking pharmaceutical solutions while continuously expanding its global presence.
Some significant milestones achieved by Sosei Group Corp include the successful completion of clinical trials for multiple novel therapeutic candidates, such as R-pasudotox, NVA237, and QVA149. The company also entered into strategic alliances and partnerships with major pharmaceutical companies, allowing for the development and commercialization of its products on a global scale. Furthermore, Sosei Group Corp successfully launched its first proprietary product, SOF-021, for chronic obstructive pulmonary disease (COPD) in Japan. These milestones demonstrate the company's commitment to innovation and market expansion, solidifying its position as a leading player in the biopharmaceutical industry.
Sosei Group Corp is primarily present in Japan and the United Kingdom.
Sosei Group Corp represents values of innovation, collaboration, and global expansion. With a commitment to creating groundbreaking pharmaceuticals, the company focuses on leveraging their proprietary drug discovery platforms to develop novel treatments for unmet medical needs. Sosei Group Corp strives to foster partnerships with other industry leaders to enhance research and development capabilities and accelerate the delivery of life-changing therapeutics to patients worldwide. Emphasizing patient-centricity, Sosei Group Corp aims to improve healthcare and contribute to society through its cutting-edge technologies and commitment to scientific excellence.
Analyytikot asettavat tällä hetkellä Nxera Pharma Co-osakkeelle keskimääräisen tavoitehinnan 1 390,11 JPY (mediaani: 1 224,00 JPY), mikä merkitsee −14,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 13 analyytikkoarvioon.
13 analyytikkoa arvioi tällä hetkellä Nxera Pharma Co-osaketta: 11 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Nxera Pharma Co-yhtiöltä 40,08 Mrd. JPY liikevaihtoa ja 43,09 JPY osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Nxera Pharma Co-osake noteerataan hintaan 8,08 EUR (1 429,00 JPY).
Nxera Pharma Co-osake (4565.T) on listattuna 4 pörssissä, muun muassa: Tokio (JPX) (4565.T), Frankfurt (JSS.F), München (JSS.MU).
The Sosei Group Corp is an innovative Japanese biopharmaceutical company that focuses on the discovery and development of new drugs. The company's business model consists of three main divisions: Sosei Heptares, Sosei NCE, and Sosei CMC. Sosei Heptares is the leading platform for the discovery and development of drugs targeting G-protein-coupled receptors (GPCRs). These receptors are an important target for a variety of diseases. Sosei Heptares has a robust pipeline with multiple clinical candidates in various therapeutic areas such as immunology, metabolism, neurology, and oncology. Key products of Sosei Heptares include the recently approved drugs Seebri Breezhaler and Utibron Neohaler for the treatment of COPD (chronic obstructive pulmonary disease). Sosei NCE focuses on the discovery and development of new drugs with innovative mechanisms of action and high therapeutic efficacy. The company is currently developing drugs for the treatment of non-infectious diseases such as cancer, inflammation, and metabolic disorders. A key product of Sosei NCE is the clinical candidate Oligo-controlled release (OCR) for the treatment of type 2 diabetes. Sosei CMC is the company's center of excellence for the chemical manufacturing of drugs. Sosei CMC offers a wide range of services, including process development, scale-up, and GMP production of NCEs, biological drugs, and inhalation products. The company has extensive experience in manufacturing drugs for clinical trials and commercial production. The business model of Sosei Group Corp is based on an integrated platform technology strategy. The company leverages its extensive expertise in GPCR research to discover innovative drug candidates that are further developed by its NCE and CMC divisions. Sosei Group Corp has entered into a number of partnerships with leading pharmaceutical companies such as AstraZeneca, Novartis, and Pfizer to accelerate the development and commercialization of its products. The company also aims to have a strong presence in the Japanese market and collaborates closely with Japanese companies such as Takeda Pharmaceutical, Ono Pharmaceutical, and Astellas Pharma. In addition, Sosei Group Corp has built a global presence by establishing branches and subsidiaries in North America, Europe, and Asia. In summary, Sosei Group Corp develops and markets innovative drug candidates through its integrated platform technology strategy, aiming to improve healthcare worldwide. The various divisions focusing on drug discovery, development, and chemical manufacturing form the foundation of this business model.
odotettu liikevaihto Nxera Pharma Co on 40,08 Mrd. JPY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Nxera Pharma Co on 3,89 Mrd. JPY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Nxera Pharma Co:n hinta-voitto-suhde (P/E) on tällä hetkellä 33,16. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Nxera Pharma Co-osakkeen arvostusta.
Nxera Pharma Co:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,22. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Nxera Pharma Co-osakkeen arvostuskennuslukuna.
Nxera Pharma Co:n Eulpool-laatuscore on 4/10.
Nxera Pharma Co:n ISIN on JP3431300007. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Nxera Pharma Co:n WKN on A0B7EK. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Nxera Pharma Co:n ticker on 4565.T. Tämä pörssinoteeraus käytetään Nxera Pharma Co-osakkeiden kauppaan pörssissä.
Nxera Pharma Co osake
Nxera Pharma Co vertaisryhmä
Nxera Pharma Co Ticker
Nxera Pharma Co FIGI
Kaikki tunnusluvut ja syvällinen analyysi Nxera Pharma Co:sta
Meidän osakeanalyysimme Nxera Pharma Co-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Nxera Pharma Co:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: